T. Wyant

D. Mould, T. Wyant, A. Parikh, 2019, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases.

DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies

Huyuan Yang, W. Sandborn, B. Feagan, 2014 .

Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin: P-0025.

T. Wyant, D. Soler, E. Fedyk, 2008 .

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab

T. Wyant, E. Fedyk, A. Parikh, 2017, Clinical Pharmacokinetics.

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab

T. Wyant, Lili Yang, Jose Estevam, 2016, Cytometry. Part B, Clinical cytometry.

Autoantibodies to Band 3 during Aging and Disease and Aging Interventions a

M. Kay, T. Wyant, J. Goodman, 1994, Annals of the New York Academy of Sciences.

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

M. Rugge, F. Gao, M. Fassan, 2017, PloS one.

Whole blood microvolume laser scanning cytometry for monitoring resting and activated platelets

A. Kantor, Patrick C. Smith, T. Wyant, 2001, Platelets.

Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Suzanne F. Jones, J. Bendell, R. Cohen, 2010 .

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

P. Rutgeerts, S. Hanauer, B. Sands, 2013, The New England journal of medicine.

Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.

Lindsay King, Viswanath Devanarayan, Steve Keller, 2015, Bioanalysis.

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

R. Egan, T. Chapman, T. Wyant, 2009, Journal of Pharmacology and Experimental Therapeutics.

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

P. Tak, Lars Klareskog, D. Gerlag, 2008, Arthritis and rheumatism.

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes

T. Wyant, E. Fedyk, Lili Yang, 2013, mAbs.

Recommendations for the development and validation of flow cytometry‐based receptor occupancy assays

John Ferbas, Virginia Litwin, Carl-Magnus Högerkorp, 2016, Cytometry. Part B, Clinical cytometry.

Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain CVD 908-htrA 1

M. Levine, C. Tacket, M. Sztein, 2003, The Journal of Immunology.

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Huyuan Yang, T. Dassopoulos, B. Sands, 2018, Inflammatory bowel diseases.

MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.

P. Tak, D. Gerlag, L. V. von Moltke, 2009, Arthritis and rheumatism.

Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates

K. Burke, Hua Yang, V. Csizmadia, 2012, Inflammatory bowel diseases.

Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region.

J. Xu, Mingxiu Hu, M. Davidson, 2011, The American journal of cardiology.

Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials

T. Wyant, Lili Yang, M. Rosario, 2020, The AAPS Journal.

P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

Huyuan Yang, W. Sandborn, B. Feagan, 2013 .

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

B. Feagan, T. Wyant, A. Parikh, 2014, Gut.

Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522

Jing Xu, P. Rutgeerts, S. Hanauer, 2012 .

Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers

B. Feagan, T. Wyant, A. Parikh, 2016, Clinical Drug Investigation.

CVD 908-htrA Serovar Typhi Strain Salmonella enterica withCell Responses in Volunteers Immunized T + and CD 8 + Concomitant Induction of CD 4

M. Levine, C. Tacket, M. Sztein, 2003 .

Potent Immunoregulatory Effects of Salmonella typhi Flagella on Antigenic Stimulation of Human Peripheral Blood Mononuclear Cells

M. Sztein, T. Wyant, M. Tanner, 1999, Infection and Immunity.

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

J. Infante, A. Daud, Hongwei Wang, 2017 .

Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer

M. Ramachandra, Adam S. Lazorchak, D. Tuck, 2017 .

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

Julie Zhang, E. Greenfield, D. Bradley, 2018, PloS one.

943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

P. Rutgeerts, S. Hanauer, B. Sands, 2012 .

P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers

J. Berger, T. Wyant, C. Milch, 2012 .

Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers: P-136.

J. Berger, T. Wyant, C. Milch, 2011 .

Preclinical Imaging in Oncology: Considerations and Recommendations for the Imaging Scientist

D. Bradley, T. Wyant, 2014 .

Mingxiu Hu, M. Davidson, T. Wyant, 2011, The American journal of cardiology.

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

P. Tak, Lars Klareskog, D. Gerlag, 2008, Arthritis and rheumatism.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

J. Berger, T. Wyant, A. Parikh, 2013, Journal of Neuroimmunology.

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.

D. Ryan, W. Messersmith, T. Kalebic, 2014 .